217 related articles for article (PubMed ID: 16166328)
1. Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses.
Dercamp C; Chemin K; Caux C; Trinchieri G; Vicari AP
Cancer Res; 2005 Sep; 65(18):8479-86. PubMed ID: 16166328
[TBL] [Abstract][Full Text] [Related]
2. CD4(+)CD25(+) regulatory T cells attenuate Hypersensitivity Pneumonitis by suppressing IFN-gamma production by CD4(+) and CD8(+) T cells.
Park Y; Oh SJ; Chung DH
J Leukoc Biol; 2009 Dec; 86(6):1427-37. PubMed ID: 19741155
[TBL] [Abstract][Full Text] [Related]
3. CD4+ CD25+ [corrected] regulatory T cells render naive CD4+ CD25- T cells anergic and suppressive.
Qiao M; Thornton AM; Shevach EM
Immunology; 2007 Apr; 120(4):447-55. PubMed ID: 17244157
[TBL] [Abstract][Full Text] [Related]
4. Role of bone marrow stromal cells in the generation of human CD8+ regulatory T cells.
Poggi A; Zocchi MR
Hum Immunol; 2008 Nov; 69(11):755-9. PubMed ID: 18817823
[TBL] [Abstract][Full Text] [Related]
5. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
Ghiringhelli F; Ménard C; Terme M; Flament C; Taieb J; Chaput N; Puig PE; Novault S; Escudier B; Vivier E; Lecesne A; Robert C; Blay JY; Bernard J; Caillat-Zucman S; Freitas A; Tursz T; Wagner-Ballon O; Capron C; Vainchencker W; Martin F; Zitvogel L
J Exp Med; 2005 Oct; 202(8):1075-85. PubMed ID: 16230475
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand.
Kosiewicz MM; Alard P; Liang S; Clark SL
Int Immunol; 2004 May; 16(5):697-706. PubMed ID: 15096489
[TBL] [Abstract][Full Text] [Related]
7. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.
Viehl CT; Moore TT; Liyanage UK; Frey DM; Ehlers JP; Eberlein TJ; Goedegebuure PS; Linehan DC
Ann Surg Oncol; 2006 Sep; 13(9):1252-8. PubMed ID: 16952047
[TBL] [Abstract][Full Text] [Related]
8. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.
Berhanu A; Huang J; Alber SM; Watkins SC; Storkus WJ
Cancer Res; 2006 May; 66(9):4895-903. PubMed ID: 16651446
[TBL] [Abstract][Full Text] [Related]
9. Basophils can directly present or cross-present antigen to CD8 lymphocytes and alter CD8 T cell differentiation into IL-10-producing phenotypes.
Kim S; Shen T; Min B
J Immunol; 2009 Sep; 183(5):3033-9. PubMed ID: 19667092
[TBL] [Abstract][Full Text] [Related]
10. Activation requirements for the induction of CD4+CD25+ T cell suppressor function.
Thornton AM; Piccirillo CA; Shevach EM
Eur J Immunol; 2004 Feb; 34(2):366-76. PubMed ID: 14768041
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo activated OVA specific and non-specific CD4+CD25+ regulatory T cells exhibit comparable suppression to OVA mediated T cell responses.
Li J; Bracht M; Shang X; Radewonuk J; Emmell E; Griswold DE; Li L
Cell Immunol; 2006 Jun; 241(2):75-84. PubMed ID: 17010326
[TBL] [Abstract][Full Text] [Related]
12. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684
[TBL] [Abstract][Full Text] [Related]
13. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.
Stoitzner P; Green LK; Jung JY; Price KM; Atarea H; Kivell B; Ronchese F
Cancer Immunol Immunother; 2008 Nov; 57(11):1665-73. PubMed ID: 18311487
[TBL] [Abstract][Full Text] [Related]
14. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10.
Larmonier N; Marron M; Zeng Y; Cantrell J; Romanoski A; Sepassi M; Thompson S; Chen X; Andreansky S; Katsanis E
Cancer Immunol Immunother; 2007 Jan; 56(1):48-59. PubMed ID: 16612596
[TBL] [Abstract][Full Text] [Related]
15. TCR transgenic CD8+ T cells activated in the presence of TGFbeta express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection.
Kapp JA; Honjo K; Kapp LM; Xu Xy; Cozier A; Bucy RP
Int Immunol; 2006 Nov; 18(11):1549-62. PubMed ID: 16966495
[TBL] [Abstract][Full Text] [Related]
16. TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets.
Pyzik M; Piccirillo CA
J Leukoc Biol; 2007 Aug; 82(2):335-46. PubMed ID: 17475784
[TBL] [Abstract][Full Text] [Related]
17. CD8+ T cells produce IL-2, which is required for CD(4+)CD25+ T cell regulation of effector CD8+ T cell development for contact hypersensitivity responses.
Kish DD; Gorbachev AV; Fairchild RL
J Leukoc Biol; 2005 Sep; 78(3):725-35. PubMed ID: 16000396
[TBL] [Abstract][Full Text] [Related]
18. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
[TBL] [Abstract][Full Text] [Related]
19. Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections.
Bachmann MF; Wolint P; Walton S; Schwarz K; Oxenius A
Eur J Immunol; 2007 Jun; 37(6):1502-12. PubMed ID: 17492805
[TBL] [Abstract][Full Text] [Related]
20. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
